Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
Condition(s) studied
Investigational drug(s) / intervention(s)
Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy: Follow-up visits at baseline, 3-months, and 1-year
Study summary
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
Eligibility
Primary outcome measure(s)
- All causes mortality — For approximately a median of 3 years
Occurrence of all cause death - Cardiovascular mortality — For approximately a median of 3 years
Occurrence of cardiovascular mortality - Cancer therapy-related cardiovascular toxicity — For approximately a median of 3 years
Occurrence of cancer therapy-related cardiovascular toxicity
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Bologna | Bologna | Italy | Not Yet Recruiting |
| Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" | Palermo | Italy | Not Yet Recruiting |
| Ss. Cyril and Methodius University in Skopje, University Clinic | Skopje | North Macedonia | Recruiting |
| University of Belgrade, Clinical Center of Serbia | Belgrade | Serbia | Recruiting |
| University of Belgrade, Clinical Hospital Center Bezanijska kosa | Belgrade | Serbia | Recruiting |
More University of Bologna trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06086132 on ClinicalTrials.gov ↗ ← All trials in Italy